Insilico Medicine highlights AI-powered biological target discovery for rare sinonasal cancer
Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the publication of a collaborative study in the journal npj Precision Oncology.